Journals A-Z
All Subjects
Free Journals
sciepub.com
Journal of Cancer Research and Treatment
ISSN (Print): 2374-1996 ISSN (Online): 2374-2003 Website: https://www.sciepub.com/journal/jcrt Editor-in-chief: Jean Rommelaere
Open Access
Journal Browser
Go
Issue 1, Volume 10
Article Metrics
  • 6242
    Views
  • 7857
    Saves
  • 0
    Citations
  • 5
    Likes
Export Article
Journal of Cancer Research and Treatment. 2022, 10(1), 1-11
DOI: 10.12691/jcrt-10-1-1
Open AccessArticle

Impact of miRNA Alteration on Cancer Pathogenesis

Emmanuel Atiatorme1, and Richard Osafo2

1Department of Biotechnology, Andhra University, College of Advance Sciences Technology, Visakhapatnam, India

2School of Health and life sciences, university of the west of Scotland, paisley campus, Scotland, UK

Pub. Date: March 11, 2022
View Full Text Full Text PDF (413 KB) Full Text ePUB(1638 KB)

Cite this paper:
Emmanuel Atiatorme and Richard Osafo. Impact of miRNA Alteration on Cancer Pathogenesis. Journal of Cancer Research and Treatment. 2022; 10(1):1-11. doi: 10.12691/jcrt-10-1-1

Abstract

MicroRNAs (miRNAs) are a type of non-coding RNA that controls gene expression post-transcriptionally through either translational repression or mRNA degradation. By regulating the translation of oncogenes and tumor suppressor genes, altered miRNA expression is linked to the development and progression of numerous human malignancies. Cleavage and translational modification of target proteins are some possible ways that miRNA affects target gene expression. MiRNAs are increasingly becoming recognized as critical regulators of biological processes such as differentiation, embryonic development, cell cycle, proliferation, apoptosis, stress resistance, fat metabolism, immunological defense, virus-related illnesses, and, most crucially, carcinogenesis. On the other hand, they appear to be key prognostic markers in patients with a variety of cancers, and they could be used as therapeutic tools. The current review focuses on recent findings in this fascinating new field of research, with a particular focus on the role of miRNA alterations in cancer pathogenesis. We explained how miRNA expression is altered in cancer at both the transcriptional and post-transcriptional levels, and how this elucidates some abnormal miRNA expression in cancer as well as some potential treatment controls for carcinogenesis. Our findings revealed that some miRNAs have evolved unique features and roles that control other transcriptional or posttranscriptional silencing pathways, resulting in carcinogenesis. The dynamic aspect of miRNA-based control in complex regulatory networks is highlighted by the evolution of miRNA processing and functional diversity. This review will aid in understanding how miRNA dysregulation affects cancer cell formation, as well as the development of more effective and secure miRNA-based therapies.

Keywords:
argonaute GW182 microRNA miRNPs translational repression

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Pearson-Stuttard, J., Zhou, B., Kontis, V., Bentham, J., Gunter, M.J., Ezzati, M, “Retracted: Worldwide burden of cancer attributable to diabetes and high body-mass index”, a comparative risk assessment, 95-104. (2018).
 
[2]  Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA,” a cancer journal for clinicians, 68(6). 394-424. Nov. 2018.
 
[3]  Moses, C., Garcia-Bloj, B., Harvey, A.R., Blancafort, P, “Hallmarks of cancer: The CRISPR generation,” European Journal of Cancer, 93.10-8. Apr 1. 2018.
 
[4]  Siege, l. R.L., Miller, K.D, Goding-Sauer, A., Fedewa, S.A, Butterly, L.F., Anderson, J.C., Cercek, A., Smith, R.A, Jemal, A,” Colorectal cancer statistics, 2020. CA,” a cancer journal for clinicians, 70(3).145-64. May. 2020.
 
[5]  Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., Bray, F, “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA”, a cancer journal for clinicians, 1(3): 209-49. May 7. 2021.
 
[6]  Mehra, M., Chauhan, R, “Long noncoding RNAs as a key player in hepatocellular carcinoma,” Biomarkers in Cancer, 9. 6-7. Nov 1. 2017.
 
[7]  Cavalieri, V., Spinelli, G,” Environmental epigenetics in zebrafish,” Epigenetics & chromatin, 10(1). 1-1. Dec. 2017.
 
[8]  Wang, M., Cai, W.R., Meng, R, Chi, J.R., Li, Y.R., Chen, A.X., Yu, Y., Cao, X.C,” miR-485-5p suppresses breast cancer progression and chemosensitivity by targeting surviving,” Biochemical and biophysical research communications, 501(1) 48-54. Jun 18. 2018.
 
[9]  Wu, X., Zeng, R., Wu, S., Zhong, J., Yang, L., Xu, J,” Comprehensive expression analysis of miRNA in breast cancer at the miRNA and isomiR levels,” Gene, 557(2). 195-200. Feb 25. 2015.
 
[10]  Eulalio, A., Huntzinger, E., Nishihara, T., Rehwinkel, J., Fauser, M., Izaurralde, E, “Deadenylation is a widespread effect of miRNA regulation,” RNA, 15(1). 21-32. Jan 1. 2009.
 
[11]  Cuperus, J.T., Fahlgren, N., Carrington, J.C, “Evolution and functional diversification of MIRNA genes,” The Plant Cell, 23(2). 431-42. Feb 1. 2011.
 
[12]  Winter, J., Jung, S., Keller, S., Gregory, R.I., Diederichs, S, “Many roads to maturity: microRNA biogenesis pathways and their regulation,” Nature cell biology, 11(3). 228-34. Mar 2009.
 
[13]  Iwasaki, S., Kobayashi, M., Yoda M., Sakaguchi, Y., Katsuma, S., Suzuki, T., Tomari, Y, “Hsc70/Hsp90 chaperone machinery mediates ATP-dependent RISC loading of small RNA duplexes,” Molecular cell, 39(2). 292-9. Jul 30. 2010.
 
[14]  Sun, X., Jiao, X., Pestell, T.G, Fan, C., Qin, S., Mirabelli, E., Ren, H., Pestell, R.G “MicroRNAs and cancer stem cells: the sword and the shield” Oncogene, 33(42). 4967-77. Oct. 2014.
 
[15]  Lotterman, C.D., Kent, O.A., Mendell, J.T”, Functional integration of microRNAs into oncogenic and tumor suppressor pathways,” Cell Cycle, 7(16).2493-9. Aug 15. 2008.
 
[16]  Yao, Y., Suo, A.L., Li, Z.F, Liu, L.Y, Tian, T., Ni, L., Zhang, W.G., Nan, K.J, Song, T.S., Huang, C, “MicroRNA profiling of human gastric cancer,” Molecular medicine reports, 2(6). 963-70. Nov 1. 2009.
 
[17]  Kim, V.N, “MicroRNA biogenesis: coordinated cropping and dicing,” Nature reviews Molecular cell biology, 6(5). 376-85. May. 2005.
 
[18]  Bartel, D.P, “MicroRNAs:.genomics, biogenesis, mechanism, and function,” Cell, 116(2). 281-97. Jan 23. 2004.
 
[19]  Zhao, Y., Samal, E., Srivastava, D, “Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis,” Nature. 436(7048). 214-20. Jul. 2005.
 
[20]  O’Donnell, K.A., Wentzel, E.A., Zeller, K.I., Dang, C.V., Mendell, J.T, “c-Myc-regulated microRNAs modulate E2F1 expression” Nature, 435(7043). 839-43. Jun. 2005.
 
[21]  Pillai, R.S, “MicroRNA function: multiple mechanisms for a tiny RNA”. Rna, 11(12).1753-61. Dec 1, 2005.
 
[22]  Sontheimer, E.J,” Assembly and function of RNA silencing complexes, “Nature Reviews Molecular Cell Biology, 6(2). 127-38. Feb. 2005.
 
[23]  Tomari, Y., Zamore, P.D, “Perspective: machines for RNAi,” Genes & development, 19(5). 517-29. Mar 1. 2005.
 
[24]  Carmell, M.A., Xuan, Z., Zhang, M.Q., Hannon, G.J, “The Argonaute family: tentacles that reach into RNAi, developmental control, stem cell maintenance, and tumorigenesis,” Genes & development. 16(21). 2733-42. Nov 1. 2002.
 
[25]  Kloosterman, W.P., Wienholds, E., Ketting, R.F, Plasterk, R.H, “Substrate requirements for let-7 function in the developing zebrafish embryo,” Nucleic acids research, 32(21). 6284-91. Jan 1. 2004.
 
[26]  Hutvágner, G., Zamore, P.D, “A microRNA in a multiple-turnover RNAi enzyme complex,” Science. 297(5589). 2056-60. Sep 20. 2002.
 
[27]  Lingel, A., Sattler, M, “Novel modes of protein–RNA recognition in the RNAi pathway”, Current opinion in structural biology, 15(1). 107-15. Feb 1. 2005.
 
[28]  Song, J.J., Smith, S.K, Hannon, G.J, “Joshua-Tor L. Crystal structure of Argonaute and its implications for RISC slicer activity”, science., 305(5689).1434-7. Sep 3. 2004.
 
[29]  Ma, J.B., Yuan, Y.R., Meister, G., Pei, Y., Tuschl, T., Patel, D.J, “Structural basis for 5′-end-specific recognition of guide RNA by the A:fulgidus Piwi protein,” Nature. 434(7033). 666-70. Mar.2005.
 
[30]  Liu, J., Carmell, M.A., Rivas, F.V., Marsden, C.G., Thomson, J.M., Song, J.J., Hammond, S.M, Joshua-Tor L., Hannon, G.J, “Argonaute2 is the catalytic engine of mammalian RNAi”, Science, 305(5689), 1437-41. Sep 3. 2004.
 
[31]  Meister, G., Tuschl, T, “Mechanisms of gene silencing by double-stranded RNA” Nature. 431(7006): 343-9. Sep.2004.
 
[32]  Rivas, F.V, “Tolia NH, Song JJ, Aragon JP, Liu J, Hannon GJ, Joshua-Tor L. Purified Argonaute2 and a siRNA form recombinant human RISC,” Nature structural & molecular biology, 12(4). 340-9. Apr. 2005.
 
[33]  Yekta, S., Shih, I.H., Bartel, D.P, “MicroRNA-directed cleavage of HOXB8 mRNA”, Science., 304(5670). 594-6. Apr 23. 2004.
 
[34]  Bagga, S., Bracht, J., Hunter, S., Massirer, K., Holtz, J., Eachus, R., Pasquinelli, A.E, “Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation,” Cell, 122(4). 553-63. Aug 26. 2005.
 
[35]  Osada, H., Takahashi, T, “MicroRNAs in biological processes and carcinogenesis”, Carcinogenesis, 28(1). 2-12. Jan 1. 2007.
 
[36]  Rehwinkel, J.A., Behm-Ansmant, I., Gatfield, D., Izaurralde, E, “A crucial role for GW182 and the DCP1: DCP2 decapping complex in miRNA-mediated gene silencing,” Rna, 11(11). 1640-7. Nov 1 2005.
 
[37]  Liu, J., Rivas, F.V., Wohlschlegel, J., Yates JR, Parker, R., Hannon, G.J, “A role for the P-body component GW182 in microRNA function,” Nature cell biology. 7(12): 1261-6. Dec. 2005.
 
[38]  Jing, Q., Huang, S., Guth, S., Zarubin, T., Motoyama, A., Chen, J., Di Padova, F., Lin, S.C., Gram, H., Han, J, “Involvement of microRNA in AU-rich element-mediated mRNA instability.” Cell, 120(5). 623-34. Mar 11. 2005.
 
[39]  Wu, L., Fan, J., Belasco, J.G, “MicroRNAs direct rapid deadenylation of mRNA,” Proceedings of the National Academy of Sciences, 103(11), 4034-9. Mar 14, 2006.
 
[40]  Andrei, M.A., Ingelfinger, D., Heintzmann, R., Achsel, T., Rivera-Pomar, R., Lührmann, R, “A role for eIF4E and eIF4E-transporter in targeting mRNPs to mammalian processing bodies”. Rna, 11(5).717-27. May 1. 2005.
 
[41]  Allegra, D., Bilan, V., Garding, A., Döhner, H., Stilgenbauer, S., Kuchenbauer, F., Mertens, D, “Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemia”, Leukemia, 28(1).98-107. Jan. 2014.
 
[42]  Pekarsky, Y., Croce, C.M, “Role of miR-15/16 in CLL,” Cell Death & Differentiation, 22(1). 6-11. Jan. 2015.
 
[43]  Zhao, J.L, Starczynowski, D.T, “Role of microRNA-146a in normal and malignant hematopoietic stem cell function”, Frontiers in genetics, 5.219. Jul 9. 2014.
 
[44]  Ali Syeda, Z., Langden, S.S., Munkhzul, C., Lee, M., Song S.J, “Regulatory mechanism of microRNA expression in cancer,” International Journal of molecular sciences, 21(5). 1723. Jan.2020.
 
[45]  Kent, O.A., Fox-Talbot, K., Halushka, M.K,” RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets,” Oncogene, 32(20).576-85. May. 2013.
 
[46]  Zeinali, T., Mansoori, B., Mohammad, A., Baradaran, B, “Regulatory mechanisms of miR-145 expression and the importance of its function in cancer metastasis,” Biomedicine & Pharmacotherapy, 109. 195-207. Jan 1. 2019.
 
[47]  He, L., He, X., Lim, L.P., De Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., Jackson, A.L, “A microRNA component of the p53 tumor suppressor network,” Nature, 447(7148). 1130-4. Jun.2007.
 
[48]  Zhang, J., Sun, Q., Zhang, Z., Ge, S., Han, Z.G., Chen, W.T., “Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop,” Oncogene. 32(1): 61-9. Jan. 2013.
 
[49]  Seipel, K., Messerli, C., Wiedemann, G., Bacher, U., Pabst, T, “MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation,” Leukemia Research, 89: 106296. Feb 1. 2020.
 
[50]  Huang, X., Ding, L., Bennewith, K.L, Tong, R.T., Welford, S.M., Ang, K.K., Story, M., Le, Q.T., Giaccia, A.J, “Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation”. Molecular cell., 35(6): 856-67. Sep 24. 2009.
 
[51]  Nallamshetty, S., Chan, S.Y., Loscalzo, J, “Hypoxia: a master regulator of microRNA biogenesis and activity,” Free Radical Biology and Medicine, 64. 20-30. Sep 9. 2013.
 
[52]  Mogilyansky, E., Rigoutsos, I, “The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease,” Cell Death & Differentiation. 20(12): 1603-14.Dec. 2013.
 
[53]  Chang, T.C., Yu, D., Lee, Y.S., Wentzel, E.A., Arking, D.E., West, K.M., Dang, C.V, Thomas-Tikhonenko, A., Mendell, J.T, “Widespread microRNA repression by Myc contributes to tumorigenesis,” Nature genetics. 40(1):43-50. Jan 2008.
 
[54]  Molenaar, J.J., Domingo-Fernández, R., Ebus ,M.E., Lindner, S., Koster ,J., Drabek, K., Mestdagh, P., Van Sluis, P., Valentijn, L.J., Van Nes, J., Broekmans, M, ”LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression”, Nature genetics, 44(11): 1199-206 Nov. 2012.
 
[55]  Gan, B., Lim, C., Chu, G., Hua, S., Ding, Z., Collins, M., Hu, J., Jiang, S., Fletcher-Sananikone, E., Zhuang, L., Chang, M, “FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis,” Cancer cell. 18(5).472-84. Nov 16. 2010.
 
[56]  Guan, T., Dominguez, C.X., Amezquita, R.A., Laidlaw, B.J., Chang, J., Henao-Mejia, J., Williams, A., Flavell, R.A., Lu, J., Kaech, S.M, “ZEB1, ZEB2, and the miR-200 family form a counter-regulatory network to regulate CD8+ T cell fates”, Journal of Experimental Medicine, 215(4): 1153-68. Apr 2. 2018.
 
[57]  Di Leva, G., Gasparini, P., Piovan, C., Ngankeu, A., Garofalo, M., Taccioli, C., Iorio, M.V., Li, M., Volinia, S., Alder, H., Nakamura, T, “MicroRNA cluster 221-222 and estrogen receptor α interactions in breast cancer”. JNCI: Journal of the National Cancer Institute, 102(10). 706-21 May 19. 2010.
 
[58]  Pinho, F.G., Frampton, A.E., Nunes, J., Krell, J., Alshaker, H., Jacob, J., Pellegrino, L., Roca-Alonso L., de Giorgio, A., Harding, V., Waxman, J, “Downregulation of microRNA-515-5p by the estrogen receptor modulates sphingosine kinase 1 and breast cancer cell proliferation”. Cancer research, 73(19). 5936-48. Oct 1, 2013.
 
[59]  Rainer, J., Ploner, C., Jesacher, S., Ploner, A., Eduardoff, M., Mansha, M., Wasim, M., Panzer-Grümayer, R., Trajanoski, Z., Niederegger, H., Kofler, R, “Glucocorticoid-regulated microRNAs and mirtrons in acute lymphoblastic leukemia,” Leukemia. 23(4):746-52. Apr.2009.
 
[60]  Takayama, K.I., Misawa, A., Inoue, S, “Significance of microRNAs in androgen signaling and prostate cancer progression” Cancers. 9(8):102. Aug. 2017.
 
[61]  Coarfa, C., Fiskus, W., Eedunuri, V.K., Rajapakshe, K., Foley, C., Chew, S.A., Shah, S.S., Geng, C., Shou, J., Mohamed, J.S, “O'Malley BW. Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer,” Oncogene, 35(18). 2345-56. May.2016.
 
[62]  Liu, C., Liu, R., Zhang, D., Deng, Q., Liu, B., Chao, H.P., Rycaj, K., Takata, Y., Lin,. K., Lu, Y., Zhong, Y, “MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes,” Nature Communications, 8(1). 1-4. Jan 23. 2017.
 
[63]  Finlay-Schultz, J., Cittelly, D.M., Hendricks, P., Patel, P., Kabos, P., Jacobsen, B.M., Richer, J.K, Sartorius, C.A, “Progesterone downregulation of miR-141 contributes to the expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a,” Oncogene, 34(28). 3676-87. Jul. 2015.
 
[64]  Cittelly, D.M., Finlay-Schultz, J., Howe, E.N., Spoelstra, N.S., Axlund, S.D., Hendricks, P., Jacobsen, B.M., Sartorius, C.A, Richer, J.K, “Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4,” Oncogene, 32(20): 2555-64. May. 2013.
 
[65]  Zhang, X., Zhao, X., Fiskus, W., Lin, J., Lwin, T., Rao, R., Zhang, Y., Chan, J.C., Fu, K., Marquez, V.E., Chen-Kiang, S, “Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas,” Cancer cell., 22(4). 506-23. Oct 16. 2012.
 
[66]  Huang, X., Ding, L., Bennewith, K.L, Tong, R.T, Welford, S.M., Ang, K.K., Story M, Le QT, Giaccia AJ. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Molecular cell, 35(6). 856-67. Sep 24. 2009.
 
[67]  Chen, P., Guo, X., Zhang, L., Zhang, W., Zhou, Q, Tian Z, Zheng, Y., Liao, Q., Wang, H., Li, G., Huang J, “MiR-200c is a cMyc-activated miRNA that promotes nasopharyngeal carcinoma by downregulating PTEN”, Oncotarget,8(3).5206. Jan 17. 2017.
 
[68]  Feng, Y.H., Tsao, C.J, “Emerging role of microRNA-21 in cancer”. Biomedical reports., 5(4). 395-402. Oct 1. 2016.
 
[69]  Volinia, S., Calin, G.A., Liu., C.G., Ambs ,S., Cimmino, A., Petrocca, F., Visone ,R., Iorio, M., Roldo C, Ferracin, M., Prueitt, R.L, “A microRNA expression signature of human solid tumors defines cancer gene targets.” Proceedings of the National Academy of Sciences, 103(7): 2257-61. Feb 14. 2006.
 
[70]  Croce, C.M, “Causes and consequences of microRNA dysregulation in cancer.” Nature reviews genetics, 10(10). 704-14. Oct .2009.
 
[71]  Esteller, M, “Cancer epigenomics: DNA methylomes and histone-modification maps”. Nature Rev. Genet. 8, 286-298. Apr (2007).
 
[72]  Saito, Y., Liang, G., Egger, G., Friedman, J.M., Chuang, J.C, Coetzee, G.A., Jones, P.A, “Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells,” Cancer cell, 9(6). 435-43. Jun 13. 2006.
 
[73]  Fabbri, M., Garzon, R., Cimmino, A., Liu, Z., Zanesi, N., Callegari, E., Liu, S., Alder, H., Costinean, S., Fernandez-Cymering, C., Volinia, S, “MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3”. Proceedings of the National Academy of Sciences, 104(40). 15805-10. Oct 2. 2007.
 
[74]  Garzon, R., Liu, S., Fabbri, M., Liu, Z, Heaphy, C.E, Callegari, E., Schwind, S., Pang, J., Yu, J., Muthusamy, N., Havelange, V, “MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1,” Blood, the Journal of the American Society of Hematology, 113(25). 6411-8. Jun 18. 2009.
 
[75]  Song, S.J, Poliseno, L., Song, M.S, Ala U, Webster, K., Ng C, Beringer, G., Brikbak, N.J, Yuan, X, Cantley, L.C., Richardson, A.L, “MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling,” Cell, 154(2). 311-24. Jul 18, 2013.
 
[76]  Schmid, G., Notaro, S., Reimer, D., Abdel-Azim, S., Duggan-Peer, M., Holly, J., Fieg,l. H., Rössler, J, Wiedemair, A., Concin, N., Altevogt, P, “Expression and promoter hypermethylation of miR-34a in the various histological subtypes of ovarian cancer”. BMC Cancer, 16(1). 1-8. Dec. 2016.
 
[77]  Wong, M.Y., Yu, Y., Walsh, W.R, Yang, J.L, “microRNA-34 family and treatment of cancers with mutant or wild-type p53,” International journal of oncology, 38(5). 1189-95. May 1. 2011.
 
[78]  Baer, C., Claus, R., Frenzel, L.P, Zucknick, M., Park, Y.J, Gu, L., Weichenhan, D., Fischer, M., Pallasch, C.P, Herpel, E., Rehli, M, “Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia”, Cancer research. 72(15). 3775-85. Aug 1. 2012.
 
[79]  Pallasch, C.P., Patz, M., Park, Y.J, Hagist ,S., Eggle, D., Claus, R., Debey-Pascher ,S., Schulz, A., Frenzel, .LP, Claasen, J., Kutsch, N, “miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia,” Blood, The Journal of the American Society of Hematology, 114(15). 3255-64. Oct 8. 2009.
 
[80]  Davalos, V., Moutinho, C., Villanueva, A., Boque, R., Silva, P., Carneiro, F., Esteller, M, “Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis”, Oncogene, 31(16): 2062-74. Apr.2012.
 
[81]  Ceppi, P., Mudduluru, G., Kumarswamy, R., Rapa I, Scagliotti, G.V, Papotti, M., Allgayer, H, “Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non–small cell lung cancer,” Molecular cancer research, 8(9): 1207-16. Sep 1. 2010.
 
[82]  Liang, Y.J, Wang, Q.Y., Zhou C.X., Yin, Q.Q., He, M, Yu, X.T, Cao, D.X, Chen, G.Q, He, J.R, Zhao, Q. “MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer,” Carcinogenesis, 34 (3).713-22. Mar 1. 2013.
 
[83]  Lujambio, A., Ropero, S., Ballestar, E., Fraga, M.F., Cerrato, C., Setién, F., Casado, S., Suarez-Gauthier, A., Sanchez-Cespedes, M., Gitt, A., Spiteri, I, “Genetic unmasking of an epigenetically silenced microRNA in human cancer cells”, Cancer Research, 67(4). 1424-9. Feb 15. 2007.
 
[84]  Tsai, K.W., Wu, C.W., Hu, L.Y., Li, S.C., Liao, Y.L., Lai, C.H., Kao, H.W., Fang, W, L., Huang, K.H, Chan, W.C., Lin, W.C, “Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer,” International journal of cancer. 129(11): 2600-10. Dec 1. 2011.
 
[85]  Nishikura, K. A, “editing of coding and non-coding RNAs by ADARs,” Nature reviews Molecular cell biology, 17(2). 83-96. Feb. 2016.
 
[86]  Park, J.E, Heo, I., Tian, Y., Simanshu, D.K., Chang, H., Jee. D., Patel, D.J., Kim, V.N,” Dicer recognizes the 5′ end of RNA for efficient and accurate processing,” Nature, 475(7355). 201-5. Jul. 2011.
 
[87]  Melo, S.A, Moutinho, C., Ropero,S., Calin. G.A., Rossi, S, Spizzo, R., Fernandez, A.F, Davalos, V., Villanueva, A., Montoya, G., Yamamoto, H, “A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells”, Cancer cell, 18(4). 303-15. Oct 19. 2010.
 
[88]  Wu, K., He, J., Pu, W., Peng, Y, “The Role of Exportin-5 in MicroRNA Biogenesis and Cancer,” Genom. Proteom. Bioinform, 16. 120-126. 2018.
 
[89]  Sun, H.L, Cui, R, Zhou, J, Teng . K.Y, Hsiao, Y.H, Nakanishi, K, Fassan, M, Luo, Z, Shi, G, Tili, E, Kutay. “H. E.R.K, activation globally downregulates miRNAs through phosphorylating exportin-5”. Cancer cell, 30(5). 723-36. Nov 14. 2016.
 
[90]  Ramírez-Moya, J., Wert-Lamas, L, Riesco-Eizaguirre, G., Santisteban, P, “Impaired microRNA processing by DICER1 downregulation endows thyroid cancer with increased aggressiveness. Oncogene, 38(27). 5486-99. Jul. 2019.
 
[91]  Caruso, S., Calderaro, J., Letouzé, E., Nault, J.C, Couchy, G., Boulai, A., Luciani, A., Zafrani, E.S., Bioulac-Sage P., Seror, O., Imbeaud, S, “Germline and somatic DICER1 mutations in familial and sporadic liver tumors”, Journal of hepatology,66(4).734-42. Apr 1. 2017.
 
[92]  Stewart, C.J., Charles A, Foulkes, W.D, “Gynecologic manifestations of the DICER1 syndrome. Surgical pathology clinics,” 9(2). 227-41. Jun 1. 2016.
 
[93]  Anglesio, M.S, Wang, Y., Yang, W., Senz, J., Wan, A., Heravi-Moussavi A, Salamanca, C., Maines-Bandiera, S., Huntsman, D.G, Morin, G.B, “Cancer-associated somatic DICER1 hotspot mutations cause defective miRNA processing and reverse-strand expression bias to predominantly mature 3p strands through loss of 5p strand cleavage”. The Journal of pathology, 229(3). 400-9. Feb. 2013.
 
[94]  Su, X, Chakravarti, D., Cho, M.S., Liu, L., Gi YJ, Lin, Y.L, Leung, M.L, El-Naggar, A., Creighton, C.J, Suraokar, M.B., Wistuba, I. “TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNA”. Nature,467(7318). 986-90. Oct. 2010.
 
[95]  Garre, P., Pérez-Segura, P., Díaz-Rubio, E., Caldés, T., de la Hoya, M, “Reassessing the TARBP2 mutation rate in hereditary nonpolyposis colorectal cancer,” Nature Genetics, 42(10). 817-8. Oct. 2010.
 
[96]  Ho, A.S., Kannan, K., Roy, D.M., Morris, L.G., Ganly, I., Katabi, N., Ramaswami, D., Walsh, L.A., Eng, S., Huse, J.T, Zhang, J, “The mutational landscape of adenoid cystic carcinoma”, Nature Genetics, 45(7). 791-8. Jul. 2013.
 
[97]  Fish, L., Navickas, A., Culbertson, B., Xu, Y., Nguyen, H.C., Zhang, S., Hochman, M., Okimoto, R., Dill, B.D, Molina, H., Najafabadi, H.S, “Nuclear TARBP2 drives oncogenic dysregulation of RNA splicing and decay,” Molecular cell, 75(5). 967-81. Sep 5. 2019.
 
[98]  Hutvagner, G., Simard, M.J, “Argonaute proteins: key players in RNA silencing. Nature reviews Molecular cell biology”, 9(1). 22-32. Jan. 2008.
 
[99]  Janas, M.M, Wang, B., Harris, A.S., Aguiar, M., Shaffer, J.M, Subrahmanyam, Y.V., Behlke, M.A., Wucherpfennig, K.W., Gygi SP., Gagnon, E., Novena, C.D, “Alternative RISC assembly: binding and repression of microRNA–mRNA duplexes by human Ago proteins,” Rna, 18(11). 2041-55. Nov 1.2012.
 
[100]  Casey, M.C, Prakash, A., Holian, E, McGuire, A., Kalinina, O., Shalaby, A., Curran, C., Webber, M., Callagy, G., Bourke, E., Kerin, M.J, “Quantifying Argonaute 2 (Ago2) expression to stratify breast cancer,” BMC Cancer, 19(1). 1-2. Dec 2019.
 
[101]  Zhang, Y., Wang, B., Chen, X., Li, W., Dong, P, “AGO2 involves the malignant phenotypes and FAK/PI3K/AKT signaling pathway in hypopharyngeal-derived FaDu cells,” Oncotarget, 8(33). 54735. Aug 15. 2017.
 
[102]  Chakraborty, C., Sharma, A.R., Sharma, G., Lee, S.S, “The interplay among miRNAs, major cytokines, and cancer-related inflammation,” Molecular Therapy-Nucleic Acids, 20.1. Apr 11. 2020.
 
[103]  Menck, K., Sönmezer, C., Worst, T.S., Schulz, M., Dihazi, G.H., Streit, F., Erdmann, G., Kling, S., Boutros, M., Binder, C., Gross, J.C, “Neutral sphingomyelinases control extracellular vesicles budding from the plasma membrane,” Journal of extracellular vesicles, 6(1). Dec 1. 2017. Sep 26.
 
[104]  Felli, N., Fontana, L., Pelosi, E., Botta, R., Bonci, D., Facchiano, F., Liuzzi, F., Lulli V., Morsilli, O., Santoro, S., Valtieri, M, “MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation,” Proceedings of the National Academy of Sciences, 102(50). 18081-6. Dec 13. 2005.
 
[105]  Chan, J.A., Krichevsky, A.M., Kosik, K.S, “MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells,” Cancer Research, 65(14). 6029-33. Jul 15. 2005.
 
[106]  Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K.G., Tuschl, T., Manoharan, M., Stoffel, M, “Silencing of microRNAs in vivo with ‘antagomirs’”, Nature, 438(7068). 685-9. Dec. 2005.
 
[107]  Takamizawa, J., Konishi, H., Yanagisawa, K., Tomida, S., Osada, H., Endoh, H., Harano, T., Yatabe, Y., Nagino, M., Nimura, Y., Mitsudomi, T, “Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival,” Cancer Research, 64(11). 3753-6. Jun 1.2004.
 
Manuscript template